CUE: Cue Biopharma Inc. Kapitalizatsiyaning foydaga nisbati

Cue Biopharma, Inc. - CUE emitenti grafik logotipi

Cue Biopharma, Inc. (CUE) uchun ushbu kunlik narxlar grafigi -0.70 qiymatini ko'rsatmoqda. Firmaning ekologik profili laboratoriya operatsiyalari davomidagi asosiy tartibga solish qoidalariga rioya qilish bilan cheklangan. Biznes modeli hozirgi ilmiy rivojlanish bosqichi tufayli bozor tebranishlari va inflyatsiyadan to'liq himoyalangan. Cue Biopharma, Inc. avtoimmun va onkologik patologiyalar uchun innovatsion davolash vositalarini tijoratlashtirish orqali daromad olishni rejalashtirmoqda.

Cue Biopharma, Inc. (CUE) - P/E multiplikatori 04.07.2022dan 14.11.2026gacha

Cue Biopharma, Inc. kompaniyasining tahliliy kesimlari

- joriy kotirovkalar va o'rtacha qiymat prognozi:
Kompaniyaning umumiy tahlili:CUE, Cue Biopharma Inc.
Cue Biopharma brend mahsuloti

Cue Biopharma, Inc. (CUE) uchun, uning yashab qolishi joriy foydadan ko'ra tashqi erta bosqichdagi ishlab chiqish moliyalashtirilishiga bog'liq bo'lgani sababli, an'anaviy narx-foyda ko'rsatkichi o'zining odatiy ma'nosini yo'qotadi. Cue Biopharma, Inc. (CUE) uchun tarixiy P/E grafigini tahlil qilib, investor kelajakdagi pul oqimlariga bo'lgan bozor kutuvlarini ko'radi, bunda koeffitsient barqaror savdo yo'qligida immunoterapiya salohiyatining spekulyativ baholanishi ko'rsatkichi bo'lib xizmat qiladi.

Raqobatdosh kompaniyalar tahlili

IBRX - Kapitalizatsiyaning sof foydaga nisbati koeffitsiyenti|Narx-foyda koeffitsiyenti IMCR (Immunocore)|JANX - Kapitalizatsiyaning foydaga nisbati|Arcus Bio - Narx-foyda koeffitsiyenti|Kompaniya qiymatining sof foydaga nisbati ZYME|Tango Therapeutics - P/E multiplikatori|Biznesning o‘zini qoplash muddati iovance.com IOVA|Immatics (IMTX) - Narxning foydaga nisbati|Narx-foyda koeffitsiyenti Xencor Inc|Narxning foydaga nisbati Compass Bio|Narx-foyda koeffitsiyenti Replimune Inc. (REPL)|Narx-foyda koeffitsiyenti LYEL (Lyell Immunopharma)|P/E multiplikatori innate-pharma.com (IPHA)|Narxning foydaga nisbati Pyxis Oncology PYXS|CGEN: Narx-foyda multiplikatori|IOBT - Narxning foydaga nisbati|Kapitalizatsiyaning foydaga nisbati Sutro Biopharma, Inc|INKT (MiNK Therapeutics, Inc.) - Narx-foyda koeffitsiyenti|Kapitalizatsiyaning sof foydaga nisbati koeffitsiyenti Werewolf Therapeutics, Inc. HOWL|Narx-foyda koeffitsiyenti IMMX|ALXO (ALX Oncology Holdings Inc.) - Bozor narxining sof foydaga nisbati|P/E multiplikatori PDSB|SONN (sonnetbio.com) - Kompaniya qiymatining sof foydaga nisbati|P/E multiplikatori MAIA (MAIA Biotechnology)|liminatuspharma.com (LIMN) - Kapitalizatsiyaning foydaga nisbati|LVTX - Narxning foydaga nisbati|Kompaniya qiymatining sof foydaga nisbati NXTC (NextCure Inc)|LPTX: P/E multiplikatori|Intensity Therapeutics, Inc. (INTS) - P/E multiplikatori|Narxning foydaga nisbati Sensei Biotherapeutics Inc|therivabio.com - Kapitalizatsiyaning sof foydaga nisbati|Narx-foyda koeffitsiyenti GRTS (Gritstone bio, Inc.)|KA - Kapitalizatsiyaning foydaga nisbati|P/E multiplikatori NEXI (NexImmune Corp)|TSBX - Narx-foyda koeffitsiyenti|VCNX: Narx-foyda koeffitsiyenti|HARP - P/E multiplikatori